Literature DB >> 15939059

A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study.

Jackie A Cooper1, George J Miller, Steve E Humphries.   

Abstract

We have compared the predictive value of the PROCAM and Framingham risk algorithms in healthy UK men from the Second Northwick Park Heart Study (NPHS-II) (50-64 years at entry), followed for a median of 10.8 years for coronary heart disease (CHD) events. For PROCAM, the area under the receiver operating characteristic (ROC) curve was 0.63 (95% CI, 0.59-0.67), and not significantly different (p = 0.46) from the Framingham score, 0.62 (0.58-0.66). Sensitivities for a 5% false-positive rate (DR(5)) were 13.8 and 12.4%, respectively. Calibration analysis for PROCAM gave a ratio of observed to expected events of 0.46 (Hosmer-Lemeshow test, p < 0.0001) and 0.47 for Framingham (p < 0.0001). Using measures taken at 5 years of high-density lipoprotein cholesterol and (estimated) low-density lipoprotein cholesterol levels increased the ROC by only 1%. An NPHS-II risk algorithm, developed using a 50% random subset, and including age, triglyceride, total cholesterol, smoking status, and systolic blood pressure at recruitment, gave an ROC of 0.64 (0.58-0.70) with a DR(5) of 10.7% when applied to the second half of the data. Adding family history and diabetes increased the DR(5) to 18.4% (p = 0.28). Adding lipoprotein(a) >26.3 mg/dL (relative risk 1.6, 1.1-2.4) gave a DR(5) of 15.5% (p = 0.55), while adding fibrinogen levels (relative risk for 1S.D. increase = 1.5, 1.1-2.0) had essentially no additional impact (DR(5) = 16.9%, p = 0.95). Thus, the PROCAM algorithm is marginally better as a risk predictor in UK men than the Framingham score, but both significantly overestimate risk in UK men. The algorithm based on NPHS-II data performs similarly to those for PROCAM and Framingham with respect to discrimination, but gave an improved ratio of observed to expected events of 0.80 (p = 0.01), although no score had a high sensitivity. Any novel factors added to these algorithms will need to have a major impact on risk to increase sensitivity above that given by classical risk factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939059     DOI: 10.1016/j.atherosclerosis.2004.12.026

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

Review 1.  Genetic testing for atherosclerosis risk: inevitability or pipe dream?

Authors:  Matthew Lanktree; Jisun Oh; Robert A Hegele
Journal:  Can J Cardiol       Date:  2008-11       Impact factor: 5.223

2.  Development of appropriate coronary heart disease risk prediction models in HIV-infected patients.

Authors:  Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; W Todd Cade; Victor G Dávila-Román; Ralph B D'Agostino; Tarek A Helmy; Matthew Law; Kristin E Mondy; Sharon Nachman; Linda R Peterson; Signe W Worm
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

3.  Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

Authors:  Judith S Currier; Jens D Lundgren; Andrew Carr; Daniel Klein; Caroline A Sabin; Paul E Sax; Jeffrey T Schouten; Marek Smieja
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

Review 4.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

Review 5.  Early identification of cardiovascular risk using genomics and proteomics.

Authors:  Iftikhar J Kullo; Leslie T Cooper
Journal:  Nat Rev Cardiol       Date:  2010-05-04       Impact factor: 32.419

Review 6.  Recommendations for raloxifene use in daily clinical practice in the Swiss setting.

Authors:  Kurt Lippuner; P A Buchard; C De Geyter; B Imthurn; O Lamy; M Litschgi; F Luzuy; K Schiessl; P Stute; M Birkhäuser
Journal:  Eur Spine J       Date:  2012-06-28       Impact factor: 3.134

Review 7.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

Review 8.  Identifying genes for coronary artery disease: An idea whose time has come.

Authors:  Robert Roberts; Alexandre F R Stewart; George A Wells; Kathryn A Williams; Nihan Kavaslar; Ruth McPherson
Journal:  Can J Cardiol       Date:  2007-08       Impact factor: 5.223

Review 9.  Genetics of coronary artery disease in the 21st century.

Authors:  Robert Roberts; Alexandre F R Stewart
Journal:  Clin Cardiol       Date:  2012-05-15       Impact factor: 2.882

10.  Kidney function and estimated vascular risk in patients with primary dyslipidemia.

Authors:  Konstantinos Tziomalos; Emmanuel S Ganotakis; Irene F Gazi; Devaki R Nair; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.